Gan to kagaku ryoho. Cancer & chemotherapy
-
Gan To Kagaku Ryoho · Feb 1995
Clinical Trial[The prevention of cancer chemotherapy-induced emesis with granisetron and clonazepam].
The antiemetic efficacy of a combination of granisetron and clonazepam was investigated in 39 gynecological cancer patients treated with cisplatin. Granisetron (3 mg/body/day) was administered by intravenous drip infusion before and 24 hours after anticancer drug administration, and clonazepam was taken orally twice a day. ⋯ Delayed emesis occurred in 38% (13/34), but the degree of nausea was mild. Clinically, antiemetic therapy with a combination of granisetron and clonazepam demonstrated superior antiemetic effects and seems to be useful for controlling nausea and vomiting associated with cancer chemotherapy.
-
Gan To Kagaku Ryoho · Feb 1995
Multicenter Study Clinical Trial[The clinical phase I study of TNP-351. The TNP-351 Research Committee].
The clinical phase I study of TNP-351, an antifolate drug having a novel structure, was performed through a multicenter cooperative program in 40 patients with solid tumors. The test drug was used on dosage schedules of single and daily doses for 5 or 3 days (by intravenous drip over 30 minutes, respectively). From the daily administration for 5 days, severe adverse reactions such as myelosuppression, became manifest at 5 mg/m2 (1n). ⋯ On the 3-day daily administration schedule, the test drug was not accumulated in vivo. In the present study, two patients with malignant fibrous histiocytoma responded to the test drug with tumor regression. The results suggested that the recommended dosage regimen for the clinical early phase II study of the test drug should comprise a course of 9 mg/m2/day (by intravenous drip infusion over 30 minutes) every day for 3 days, which should be repeated every 3 weeks.
-
Gan To Kagaku Ryoho · Feb 1995
Randomized Controlled Trial Clinical Trial[5-FU concentrations in the blood and tumor tissue after 5'-DFUR or UFT administration in the patients with uterine cervical cancer].
In order to verify the antitumor activity of fluorinated pyrimidine drugs, we conducted an investigation of the clinical pharmacology with two drugs, 5'-DFUR and UFT. Total 21 cases of cervical cancer were alloted randomly into 5'-DFUR group (daily dose 800 mg for 3 days) consisting of 11 patients and UFT group (daily dose 600 mg for 3 days) consisting of 10 patients, the unchanged substances (5'-DFUR in the 5'-DFUR group and tegafur concentrations in the UFT group) and 5-FU concentrations in serum and tissues were measured 6 hours after administration of the drugs. The 5'-DFUR concentration in the 5'-DFUR group was not detected in serum and less than a detectable limit for all of cancerous tissues, normal cervical tissues, and lymph nodes. ⋯ The 5-FU concentrations in the 5'-DFUR treated group were 0.018 +/- 0.046 micrograms/g for cancerous tissues, but less than a detectable limit for serum and normal cervical tissues. On the other hand, in the UFT group, 0.271 +/- 0.247 micrograms/g for a cancerous tissue, 0.035 +/- 0.018 micrograms/ml for serum, 0.125 +/- 0.073 micrograms/g for normal cervical tissues, showing significantly high values (p < 0.01, p < 0.001, and p < 0.01, respectively) compared to those in the 5'-DFUR treated group. These results suggest that UFT is a promising drug for the treatment of cancer of the uterine cervix.
-
Gan To Kagaku Ryoho · Jan 1995
Multicenter Study Clinical Trial[Late phase II trial of RP56976 (Docetaxel) in patients with non-small-cell lung cancer].
A late phase II trial on RP 56976 (Docetaxel) was carried out against stage IIIB or IV non-resectable non-small cell lung cancer as a multicenter cooperative trial. Of 78 enrolled patients, seventy five patients were eligible and 71 were evaluable for the response. The overall response rate was 19.7% (14/71): 27.9% (12/48) of patients with adenocarcinoma and 10.0% (2/20) of patients with squamous cell carcinoma responded to docetaxel. ⋯ Other adverse reactions included nausea/vomiting, anorexia, general malaise, alopecia, all of which were not severe. Severe hypersensitivity reactions occurred in 2 patients (2.7%). The results seemed to show usefulness of docetaxel for the treatment of patients with non-small cell lung cancer.
-
Gan To Kagaku Ryoho · Dec 1994
Case Reports[Home terminal care for terminal gastric cancer patients--case of epidural morphine injection].
Pain management at home for a terminal gastric cancer patient unable to take medications orally was made possible by a combination of serial morphine drip infusion and epidural anesthesia with morphine on a continuing basis using a disposal syringe. Before the patient was discharged, a conference was held to prepare for home care. Besides the patient and family, it was attended by the primary care doctor, ward nurse, home nurse, pharmacy staff, pain clinic doctor and hospital office personnel. ⋯ With one visit per week to the hospital and home visits by a nurse once or twice a week, the patient managed at home for 82 days before increased pain resulted in rehospitalization. After the pain was brought under control and the patient was discharged, he was again hospitalized 5 days later. The pain control up until the time of death was by drip infusion of up to 1,200 mg/day morphine.